XOMA Royalty Corporation (XOMAP) Stock Competitors & Peer Comparison
See (XOMAP) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Pharmaceuticals Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| XOMAP | $25.49 | +0.12% | 307.5M | 14.00 | $1.82 | +8.46% |
| RPRX | $56.23 | +2.82% | 24.2B | 11.09 | $5.07 | +1.64% |
| WBA | $11.98 | +0.50% | 10.4B | -1.64 | -$7.29 | +4.17% |
| KNSA | $59.20 | +4.06% | 4.5B | 65.78 | $0.90 | N/A |
| TRLV | $8.99 | +5.52% | 1.5B | 893.00 | $0.01 | N/A |
| HROWL | $25.61 | +0.19% | 1.4B | N/A | N/A | N/A |
| AVLN | $30.71 | +5.97% | 1.4B | -1.41 | -$21.83 | N/A |
| HROWM | $26.03 | -0.08% | 1.3B | N/A | N/A | N/A |
| CGEM | $18.40 | -0.43% | 1.1B | -5.48 | -$3.36 | N/A |
| IKT | $1.91 | +2.14% | 252.2M | -4.44 | -$0.43 | N/A |
Stock Comparison
XOMAP vs RPRX Comparison June 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 307.5M. In comparison, RPRX has a market cap of 24.2B. Regarding current trading prices, XOMAP is priced at $25.49, while RPRX trades at $56.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 14.00, whereas RPRX's P/E ratio is 11.09. In terms of profitability, XOMAP's ROE is +0.32%, compared to RPRX's ROE of +0.13%. Regarding short-term risk, XOMAP is less volatile compared to RPRX. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check RPRX's competition here
XOMAP vs WBA Comparison June 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 307.5M. In comparison, WBA has a market cap of 10.4B. Regarding current trading prices, XOMAP is priced at $25.49, while WBA trades at $11.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 14.00, whereas WBA's P/E ratio is -1.64. In terms of profitability, XOMAP's ROE is +0.32%, compared to WBA's ROE of -0.42%. Regarding short-term risk, XOMAP is more volatile compared to WBA. This indicates potentially higher risk in terms of short-term price fluctuations for XOMAP.Check WBA's competition here
XOMAP vs KNSA Comparison June 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 307.5M. In comparison, KNSA has a market cap of 4.5B. Regarding current trading prices, XOMAP is priced at $25.49, while KNSA trades at $59.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 14.00, whereas KNSA's P/E ratio is 65.78. In terms of profitability, XOMAP's ROE is +0.32%, compared to KNSA's ROE of +0.13%. Regarding short-term risk, XOMAP is less volatile compared to KNSA. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check KNSA's competition here
XOMAP vs TRLV Comparison June 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 307.5M. In comparison, TRLV has a market cap of 1.5B. Regarding current trading prices, XOMAP is priced at $25.49, while TRLV trades at $8.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 14.00, whereas TRLV's P/E ratio is 893.00. In terms of profitability, XOMAP's ROE is +0.32%, compared to TRLV's ROE of -0.07%. Regarding short-term risk, XOMAP is less volatile compared to TRLV. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check TRLV's competition here
XOMAP vs HROWL Comparison June 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 307.5M. In comparison, HROWL has a market cap of 1.4B. Regarding current trading prices, XOMAP is priced at $25.49, while HROWL trades at $25.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 14.00, whereas HROWL's P/E ratio is N/A. In terms of profitability, XOMAP's ROE is +0.32%, compared to HROWL's ROE of -0.34%. Regarding short-term risk, XOMAP is less volatile compared to HROWL. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check HROWL's competition here
XOMAP vs AVLN Comparison June 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 307.5M. In comparison, AVLN has a market cap of 1.4B. Regarding current trading prices, XOMAP is priced at $25.49, while AVLN trades at $30.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 14.00, whereas AVLN's P/E ratio is -1.41. In terms of profitability, XOMAP's ROE is +0.32%, compared to AVLN's ROE of +0.36%. Regarding short-term risk, XOMAP is less volatile compared to AVLN. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check AVLN's competition here
XOMAP vs HROWM Comparison June 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 307.5M. In comparison, HROWM has a market cap of 1.3B. Regarding current trading prices, XOMAP is priced at $25.49, while HROWM trades at $26.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 14.00, whereas HROWM's P/E ratio is N/A. In terms of profitability, XOMAP's ROE is +0.32%, compared to HROWM's ROE of -0.34%. Regarding short-term risk, XOMAP is more volatile compared to HROWM. This indicates potentially higher risk in terms of short-term price fluctuations for XOMAP.Check HROWM's competition here
XOMAP vs CGEM Comparison June 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 307.5M. In comparison, CGEM has a market cap of 1.1B. Regarding current trading prices, XOMAP is priced at $25.49, while CGEM trades at $18.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 14.00, whereas CGEM's P/E ratio is -5.48. In terms of profitability, XOMAP's ROE is +0.32%, compared to CGEM's ROE of -0.51%. Regarding short-term risk, XOMAP is less volatile compared to CGEM. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check CGEM's competition here
XOMAP vs IKT Comparison June 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 307.5M. In comparison, IKT has a market cap of 252.2M. Regarding current trading prices, XOMAP is priced at $25.49, while IKT trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 14.00, whereas IKT's P/E ratio is -4.44. In terms of profitability, XOMAP's ROE is +0.32%, compared to IKT's ROE of -0.41%. Regarding short-term risk, XOMAP is less volatile compared to IKT. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check IKT's competition here
XOMAP vs LFMD Comparison June 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 307.5M. In comparison, LFMD has a market cap of 199.7M. Regarding current trading prices, XOMAP is priced at $25.49, while LFMD trades at $4.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 14.00, whereas LFMD's P/E ratio is -10.68. In terms of profitability, XOMAP's ROE is +0.32%, compared to LFMD's ROE of -1.72%. Regarding short-term risk, XOMAP is less volatile compared to LFMD. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check LFMD's competition here
XOMAP vs HITI Comparison June 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 307.5M. In comparison, HITI has a market cap of 196.8M. Regarding current trading prices, XOMAP is priced at $25.49, while HITI trades at $2.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 14.00, whereas HITI's P/E ratio is 56.00. In terms of profitability, XOMAP's ROE is +0.32%, compared to HITI's ROE of -0.43%. Regarding short-term risk, XOMAP is less volatile compared to HITI. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check HITI's competition here
XOMAP vs LFMDP Comparison June 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 307.5M. In comparison, LFMDP has a market cap of 160M. Regarding current trading prices, XOMAP is priced at $25.49, while LFMDP trades at $23.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 14.00, whereas LFMDP's P/E ratio is 290.40. In terms of profitability, XOMAP's ROE is +0.32%, compared to LFMDP's ROE of -1.72%. Regarding short-term risk, XOMAP is more volatile compared to LFMDP. This indicates potentially higher risk in terms of short-term price fluctuations for XOMAP.Check LFMDP's competition here
XOMAP vs PETS Comparison June 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 307.5M. In comparison, PETS has a market cap of 37.6M. Regarding current trading prices, XOMAP is priced at $25.49, while PETS trades at $1.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 14.00, whereas PETS's P/E ratio is -1.66. In terms of profitability, XOMAP's ROE is +0.32%, compared to PETS's ROE of -1.47%. Regarding short-term risk, XOMAP is less volatile compared to PETS. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check PETS's competition here
XOMAP vs RAD Comparison June 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 307.5M. In comparison, RAD has a market cap of 36.8M. Regarding current trading prices, XOMAP is priced at $25.49, while RAD trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 14.00, whereas RAD's P/E ratio is -0.05. In terms of profitability, XOMAP's ROE is +0.32%, compared to RAD's ROE of +2.76%. Regarding short-term risk, XOMAP is less volatile compared to RAD. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check RAD's competition here
XOMAP vs YI Comparison June 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 307.5M. In comparison, YI has a market cap of 36.5M. Regarding current trading prices, XOMAP is priced at $25.49, while YI trades at $4.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 14.00, whereas YI's P/E ratio is -2.99. In terms of profitability, XOMAP's ROE is +0.32%, compared to YI's ROE of +0.14%. Regarding short-term risk, XOMAP is less volatile compared to YI. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check YI's competition here
XOMAP vs GLTO Comparison June 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 307.5M. In comparison, GLTO has a market cap of 34.5M. Regarding current trading prices, XOMAP is priced at $25.49, while GLTO trades at $21.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 14.00, whereas GLTO's P/E ratio is -1.78. In terms of profitability, XOMAP's ROE is +0.32%, compared to GLTO's ROE of -1.22%. Regarding short-term risk, XOMAP is less volatile compared to GLTO. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check GLTO's competition here
XOMAP vs SDEV Comparison June 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 307.5M. In comparison, SDEV has a market cap of 29.6M. Regarding current trading prices, XOMAP is priced at $25.49, while SDEV trades at $1.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 14.00, whereas SDEV's P/E ratio is -0.19. In terms of profitability, XOMAP's ROE is +0.32%, compared to SDEV's ROE of +17.15%. Regarding short-term risk, XOMAP is less volatile compared to SDEV. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check SDEV's competition here
XOMAP vs KYNB Comparison June 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 307.5M. In comparison, KYNB has a market cap of 29.3M. Regarding current trading prices, XOMAP is priced at $25.49, while KYNB trades at $7.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 14.00, whereas KYNB's P/E ratio is -0.59. In terms of profitability, XOMAP's ROE is +0.32%, compared to KYNB's ROE of -2.34%. Regarding short-term risk, XOMAP is less volatile compared to KYNB. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check KYNB's competition here
XOMAP vs NSRX Comparison June 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 307.5M. In comparison, NSRX has a market cap of 29.1M. Regarding current trading prices, XOMAP is priced at $25.49, while NSRX trades at $3.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 14.00, whereas NSRX's P/E ratio is -4.69. In terms of profitability, XOMAP's ROE is +0.32%, compared to NSRX's ROE of +0.00%. Regarding short-term risk, XOMAP is less volatile compared to NSRX. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check NSRX's competition here
XOMAP vs RNTX Comparison June 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 307.5M. In comparison, RNTX has a market cap of 27.2M. Regarding current trading prices, XOMAP is priced at $25.49, while RNTX trades at $0.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 14.00, whereas RNTX's P/E ratio is -0.55. In terms of profitability, XOMAP's ROE is +0.32%, compared to RNTX's ROE of -2.58%. Regarding short-term risk, XOMAP is less volatile compared to RNTX. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check RNTX's competition here
XOMAP vs NEUP Comparison June 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 307.5M. In comparison, NEUP has a market cap of 24.7M. Regarding current trading prices, XOMAP is priced at $25.49, while NEUP trades at $4.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 14.00, whereas NEUP's P/E ratio is -0.41. In terms of profitability, XOMAP's ROE is +0.32%, compared to NEUP's ROE of -1.10%. Regarding short-term risk, XOMAP is less volatile compared to NEUP. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check NEUP's competition here
XOMAP vs SCYX Comparison June 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 307.5M. In comparison, SCYX has a market cap of 24.2M. Regarding current trading prices, XOMAP is priced at $25.49, while SCYX trades at $3.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 14.00, whereas SCYX's P/E ratio is -1.13. In terms of profitability, XOMAP's ROE is +0.32%, compared to SCYX's ROE of -0.57%. Regarding short-term risk, XOMAP is less volatile compared to SCYX. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check SCYX's competition here
XOMAP vs RKTO Comparison June 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 307.5M. In comparison, RKTO has a market cap of 21.2M. Regarding current trading prices, XOMAP is priced at $25.49, while RKTO trades at $0.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 14.00, whereas RKTO's P/E ratio is -1.05. In terms of profitability, XOMAP's ROE is +0.32%, compared to RKTO's ROE of -1.65%. Regarding short-term risk, XOMAP is less volatile compared to RKTO. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check RKTO's competition here
XOMAP vs MEDS Comparison June 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 307.5M. In comparison, MEDS has a market cap of 13.3M. Regarding current trading prices, XOMAP is priced at $25.49, while MEDS trades at $7.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 14.00, whereas MEDS's P/E ratio is -0.31. In terms of profitability, XOMAP's ROE is +0.32%, compared to MEDS's ROE of -1.21%. Regarding short-term risk, XOMAP is less volatile compared to MEDS. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check MEDS's competition here
XOMAP vs BFRI Comparison June 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 307.5M. In comparison, BFRI has a market cap of 12.4M. Regarding current trading prices, XOMAP is priced at $25.49, while BFRI trades at $0.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 14.00, whereas BFRI's P/E ratio is -0.91. In terms of profitability, XOMAP's ROE is +0.32%, compared to BFRI's ROE of -4.77%. Regarding short-term risk, XOMAP is less volatile compared to BFRI. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check BFRI's competition here
XOMAP vs POM Comparison June 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 307.5M. In comparison, POM has a market cap of 10M. Regarding current trading prices, XOMAP is priced at $25.49, while POM trades at $1.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 14.00, whereas POM's P/E ratio is -0.29. In terms of profitability, XOMAP's ROE is +0.32%, compared to POM's ROE of +0.07%. Regarding short-term risk, XOMAP is less volatile compared to POM. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check POM's competition here
XOMAP vs CJJD Comparison June 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 307.5M. In comparison, CJJD has a market cap of 9.9M. Regarding current trading prices, XOMAP is priced at $25.49, while CJJD trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 14.00, whereas CJJD's P/E ratio is -0.46. In terms of profitability, XOMAP's ROE is +0.32%, compared to CJJD's ROE of -0.25%. Regarding short-term risk, XOMAP is less volatile compared to CJJD. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check CJJD's competition here
XOMAP vs MSLE Comparison June 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 307.5M. In comparison, MSLE has a market cap of 9.1M. Regarding current trading prices, XOMAP is priced at $25.49, while MSLE trades at $7.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 14.00, whereas MSLE's P/E ratio is -5.20. In terms of profitability, XOMAP's ROE is +0.32%, compared to MSLE's ROE of -0.67%. Regarding short-term risk, XOMAP is less volatile compared to MSLE. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check MSLE's competition here
XOMAP vs SSY Comparison June 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 307.5M. In comparison, SSY has a market cap of 7.9M. Regarding current trading prices, XOMAP is priced at $25.49, while SSY trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 14.00, whereas SSY's P/E ratio is -2.86. In terms of profitability, XOMAP's ROE is +0.32%, compared to SSY's ROE of -0.15%. Regarding short-term risk, XOMAP is less volatile compared to SSY. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check SSY's competition here
XOMAP vs AIXC Comparison June 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 307.5M. In comparison, AIXC has a market cap of 5.6M. Regarding current trading prices, XOMAP is priced at $25.49, while AIXC trades at $1.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 14.00, whereas AIXC's P/E ratio is -0.13. In terms of profitability, XOMAP's ROE is +0.32%, compared to AIXC's ROE of -0.94%. Regarding short-term risk, XOMAP is less volatile compared to AIXC. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check AIXC's competition here
XOMAP vs HKPD Comparison June 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 307.5M. In comparison, HKPD has a market cap of 4M. Regarding current trading prices, XOMAP is priced at $25.49, while HKPD trades at $0.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 14.00, whereas HKPD's P/E ratio is -6.02. In terms of profitability, XOMAP's ROE is +0.32%, compared to HKPD's ROE of -0.01%. Regarding short-term risk, XOMAP is less volatile compared to HKPD. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check HKPD's competition here
XOMAP vs PAVS Comparison June 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 307.5M. In comparison, PAVS has a market cap of 3.7M. Regarding current trading prices, XOMAP is priced at $25.49, while PAVS trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 14.00, whereas PAVS's P/E ratio is N/A. In terms of profitability, XOMAP's ROE is +0.32%, compared to PAVS's ROE of -0.28%. Regarding short-term risk, XOMAP is less volatile compared to PAVS. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check PAVS's competition here
XOMAP vs MDVL Comparison June 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 307.5M. In comparison, MDVL has a market cap of 2.9M. Regarding current trading prices, XOMAP is priced at $25.49, while MDVL trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 14.00, whereas MDVL's P/E ratio is -0.05. In terms of profitability, XOMAP's ROE is +0.32%, compared to MDVL's ROE of -2.39%. Regarding short-term risk, XOMAP is less volatile compared to MDVL. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check MDVL's competition here
XOMAP vs ATNFW Comparison June 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 307.5M. In comparison, ATNFW has a market cap of 2.6M. Regarding current trading prices, XOMAP is priced at $25.49, while ATNFW trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 14.00, whereas ATNFW's P/E ratio is N/A. In terms of profitability, XOMAP's ROE is +0.32%, compared to ATNFW's ROE of -2.41%. Regarding short-term risk, XOMAP is less volatile compared to ATNFW. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check ATNFW's competition here
XOMAP vs BGMSP Comparison June 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 307.5M. In comparison, BGMSP has a market cap of 2.4M. Regarding current trading prices, XOMAP is priced at $25.49, while BGMSP trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 14.00, whereas BGMSP's P/E ratio is N/A. In terms of profitability, XOMAP's ROE is +0.32%, compared to BGMSP's ROE of -0.51%. Regarding short-term risk, XOMAP is less volatile compared to BGMSP. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check BGMSP's competition here
XOMAP vs AZNH Comparison June 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 307.5M. In comparison, AZNH has a market cap of 1.6M. Regarding current trading prices, XOMAP is priced at $25.49, while AZNH trades at $53.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 14.00, whereas AZNH's P/E ratio is 38.35. In terms of profitability, XOMAP's ROE is +0.32%, compared to AZNH's ROE of +0.00%. Regarding short-term risk, XOMAP is less volatile compared to AZNH. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check AZNH's competition here
XOMAP vs BGMS Comparison June 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 307.5M. In comparison, BGMS has a market cap of 1.3M. Regarding current trading prices, XOMAP is priced at $25.49, while BGMS trades at $0.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 14.00, whereas BGMS's P/E ratio is -0.17. In terms of profitability, XOMAP's ROE is +0.32%, compared to BGMS's ROE of -0.51%. Regarding short-term risk, XOMAP is less volatile compared to BGMS. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check BGMS's competition here
XOMAP vs LFLYW Comparison June 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 307.5M. In comparison, LFLYW has a market cap of 299.9K. Regarding current trading prices, XOMAP is priced at $25.49, while LFLYW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 14.00, whereas LFLYW's P/E ratio is -0.04. In terms of profitability, XOMAP's ROE is +0.32%, compared to LFLYW's ROE of +0.17%. Regarding short-term risk, XOMAP is more volatile compared to LFLYW. This indicates potentially higher risk in terms of short-term price fluctuations for XOMAP.Check LFLYW's competition here
XOMAP vs SHPG Comparison June 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 307.5M. In comparison, SHPG has a market cap of 0. Regarding current trading prices, XOMAP is priced at $25.49, while SHPG trades at $179.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 14.00, whereas SHPG's P/E ratio is N/A. In terms of profitability, XOMAP's ROE is +0.32%, compared to SHPG's ROE of +0.13%. Regarding short-term risk, XOMAP is more volatile compared to SHPG. This indicates potentially higher risk in terms of short-term price fluctuations for XOMAP.Check SHPG's competition here
XOMAP vs CPD Comparison June 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 307.5M. In comparison, CPD has a market cap of 0. Regarding current trading prices, XOMAP is priced at $25.49, while CPD trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 14.00, whereas CPD's P/E ratio is N/A. In terms of profitability, XOMAP's ROE is +0.32%, compared to CPD's ROE of N/A. Regarding short-term risk, XOMAP is less volatile compared to CPD. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check CPD's competition here
XOMAP vs OREX Comparison June 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 307.5M. In comparison, OREX has a market cap of 0. Regarding current trading prices, XOMAP is priced at $25.49, while OREX trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 14.00, whereas OREX's P/E ratio is N/A. In terms of profitability, XOMAP's ROE is +0.32%, compared to OREX's ROE of -0.54%. Regarding short-term risk, XOMAP is less volatile compared to OREX. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check OREX's competition here
XOMAP vs ESRX Comparison June 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 307.5M. In comparison, ESRX has a market cap of 0. Regarding current trading prices, XOMAP is priced at $25.49, while ESRX trades at $92.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 14.00, whereas ESRX's P/E ratio is N/A. In terms of profitability, XOMAP's ROE is +0.32%, compared to ESRX's ROE of +0.26%. Regarding short-term risk, XOMAP is more volatile compared to ESRX. This indicates potentially higher risk in terms of short-term price fluctuations for XOMAP.Check ESRX's competition here
XOMAP vs POZN Comparison June 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 307.5M. In comparison, POZN has a market cap of 0. Regarding current trading prices, XOMAP is priced at $25.49, while POZN trades at $5.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 14.00, whereas POZN's P/E ratio is N/A. In terms of profitability, XOMAP's ROE is +0.32%, compared to POZN's ROE of +0.61%. Regarding short-term risk, XOMAP is less volatile compared to POZN. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check POZN's competition here
XOMAP vs IPXL Comparison June 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 307.5M. In comparison, IPXL has a market cap of 0. Regarding current trading prices, XOMAP is priced at $25.49, while IPXL trades at $18.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 14.00, whereas IPXL's P/E ratio is N/A. In terms of profitability, XOMAP's ROE is +0.32%, compared to IPXL's ROE of -1.16%. Regarding short-term risk, XOMAP is less volatile compared to IPXL. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check IPXL's competition here